Otential, BPND) in healthy individuals after six months of supplementation. In addition, we hypothesized that this increased availability of VMAT2 will lead to greater vesicular dopamine stores and improve dopamine-dependent working memory, which was measured using a verbal n-back task and three working memory loads (1-back, 2-back and 3-back).drug abuse and pregnancy. In addition to this subjects underwent a complete blood cell count, liver function test, fasting lipid profile and RBC for fatty acid analysis at 1-month, 3-months, 5-months to monitor for abnormal lab results (such as elevations in liver function tests and low-density lipoproteins and reduction in platelet count) and confirmed adherence to n? PUFA. The monitoring led to discontinuation on n? PUFA supplementation in two individuals ne for elevated low-density lipoproteins (193 mg/dl) and another for low platelet counts (120,000/mL) at 1month and 5-months post-supplementation respectively (these abnormal laboratory Felypressin values reverted back to normal range after discontinuation in both these subjects). Thus, the final sample includes pre- and post-supplementation data in only 11 out of the 13 enrolled subjects.RBC Fatty Acid CompositionFasting blood samples were processed for the separation of RBC membranes using previously methods and stored at 280 degree Celsius [18]. These frozen RBC samples were analyzed for fatty acid composition using gas chromatography [19]. Individual PUFA levels are expressed as percentages of the total fatty acid pool (weight or mol ).Materials and Methods Ethics 
StatementThe study was conducted following the approvals of the University of Pittsburgh Institutional Review Board and Radioactive Drug Research Committee. All subjects provided written informed consent. Study criteria for healthy controls were [1] males or females between 18 and 25 years old, of all ethnic and racial origins; [2] no past or current Diagnostic 15755315 and Statistical Manual of Mental Disorders IV criteria for psychiatric disorders, including addiction to drugs, alcohol or nicotine (as confirmed by urine drug screen at screening) [3] not currently on any prescription or over the counter medications including vitamins or herbal supplements; [4] female subjects were not currently pregnant and used of an effective birth control such as intrauterine contraceptive device, oral contraceptive pills during the entire course of the study; [5] no current or past severe medical or neurological illnesses (including glaucoma, seizure disorders, a focal finding on magnetic resonance imaging, MRI such as stroke or tumor) as assessed by a complete medical assessment; [6] no hypersensitivity to fish or shell fish; [7] no history of significant radioactivity exposure (nuclear medicine studies or occupational exposure); [8] no metallic objects in the body that are contraindicated for MRI; [9] no Lixisenatide chemical information drinking of more than two standard alcoholic drinks per day; [10] no first degree relatives with an Axis I psychiatric disorder; [11] no consumption of fish more than twice a month or currently on fish oil supplements. A total of thirteen subjects who met inclusion/exclusion criteria (as determined by a structured clinical interview for DSM IV, medical evaluation, electrocardiogram, and routine blood and urine tests, which included a drug screen and pregnancy test) were enrolled to participate in the study that was conducted in the outpatient setting. All enrolled subjects underwent a pre-supplementation [11C.Otential, BPND) in healthy individuals after six months of supplementation. In addition, we hypothesized that this increased availability of VMAT2 will lead to greater vesicular dopamine stores and improve dopamine-dependent working memory, which was measured using a verbal n-back task and three working memory loads (1-back, 2-back and 3-back).drug abuse and pregnancy. In addition to this subjects underwent a complete blood cell count, liver function test, fasting lipid profile and RBC for fatty acid analysis at 1-month, 3-months, 5-months to monitor for abnormal lab results (such as elevations in liver function tests and low-density lipoproteins and reduction in platelet count) and confirmed adherence to n? PUFA. The monitoring led to discontinuation on n? PUFA supplementation in two individuals ne for elevated low-density lipoproteins (193 mg/dl) and another for low platelet counts (120,000/mL) at 1month and 5-months post-supplementation respectively (these abnormal laboratory values reverted back to normal range after discontinuation in both these subjects). Thus, the final sample includes pre- and post-supplementation data in only 11 out of the 13 enrolled subjects.RBC Fatty Acid CompositionFasting blood samples were processed for the separation of RBC membranes using previously methods and stored at 280 degree Celsius [18]. These frozen RBC samples were analyzed for fatty acid composition using gas chromatography [19]. Individual PUFA levels are expressed as percentages of the total fatty acid pool (weight or mol ).Materials and Methods Ethics StatementThe study was conducted following the approvals of the University of Pittsburgh Institutional Review Board and Radioactive Drug Research Committee. All subjects provided written informed consent. Study criteria for healthy controls were [1] males or females between 18 and 25 years old, of all ethnic and racial origins; [2] no past or current Diagnostic 15755315 and Statistical Manual of Mental Disorders IV criteria for psychiatric disorders, including addiction to drugs, alcohol or nicotine (as confirmed by urine drug screen at screening) [3] not currently on any prescription or over the counter medications including vitamins or herbal supplements; [4] female subjects were not currently pregnant and used of an effective birth control such as intrauterine contraceptive device, oral contraceptive pills during the entire course of the study; [5] no current or past severe medical or neurological illnesses (including glaucoma, seizure disorders, a focal finding on magnetic resonance imaging, MRI such as stroke or tumor) as assessed by a complete medical assessment; [6] no hypersensitivity to fish or shell fish; [7] no history 
of significant radioactivity exposure (nuclear medicine studies or occupational exposure); [8] no metallic objects in the body that are contraindicated for MRI; [9] no drinking of more than two standard alcoholic drinks per day; [10] no first degree relatives with an Axis I psychiatric disorder; [11] no consumption of fish more than twice a month or currently on fish oil supplements. A total of thirteen subjects who met inclusion/exclusion criteria (as determined by a structured clinical interview for DSM IV, medical evaluation, electrocardiogram, and routine blood and urine tests, which included a drug screen and pregnancy test) were enrolled to participate in the study that was conducted in the outpatient setting. All enrolled subjects underwent a pre-supplementation [11C.